Identification of longitudinally dynamic biomarkers in Alzheimer's disease cerebrospinal fluid by targeted proteomics

Molecular Neurodegeneration

Volumn 9, Issue 1, 2014, Pages

  Wildsmith, Kristin R ^a   Schauer, Stephen P ^a   Smith, Ashley M ^a   Arnott, David ^a   Zhu, Yuda ^a   Haznedar, Joshua ^a   Kaur, Surinder ^a   Mathews, W Rodney ^a   Honigberg, Lee A ^a  

^a GENENTECH INC   (United States)

Author keywords

Alzheimer's disease; Biomarkers; Cerebrospinal fluid; LC MS; Mass spectrometry; Multiple reaction monitoring; Targeted proteomics

Indexed keywords

ALBUMIN; ALPHA 1 ANTITRYPSIN; ALPHA 1 BETA GLYCOPROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; APOLIPOPROTEIN E4; AXONIN 1; BETA 2 MICROGLOBULIN; BETA2 GLYCOPROTEIN 1; BIOLOGICAL MARKER; CERULOPLASMIN; CHITINASE; CHITINASE 3 LIKE PROTEIN 1; CHROMOGRANIN A; CLUSTERIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CONTACTIN 1; CYSTATIN C; GLYCOPROTEIN; NEURONAL PENTRAXIN RECEPTOR; PLASMINOGEN; PRION PROTEIN; PROSTAGLANDIN D2 DERIVATIVE; PROSTAGLANDIN D2 SYNTHASE; RECEPTOR; RETINOL BINDING PROTEIN; SUPEROXIDE DISMUTASE; TAU PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FREEZE THAWING; HUMAN; LIMIT OF QUANTITATION; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; MONITORING; MULTIPLE REACTION MONITORING; PROTEIN ANALYSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEOMICS;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROTEOMICS;

EID: 84902808236     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-9-22     Document Type: Article

References (79)

1. Alzheimer's disease facts and figures. Thies W, Bleiler L, Alzheimers Dement 2013 9 2 208 245 23507120
2. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH, Bergeson J, Manetti GJ, Zimmermann M, Tang B, Bartko JJ, Cohen RM, JAMA 2003 289 16 2094 2103 12709467 (Pubitemid 37430211)
3. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Clark CM, Xie S, Chittams J, Ewbank D, Peskind E, Galasko D, Morris JC, McKeel DW Jr, Farlow M, Weitlauf SL, Quinn J, Kaye J, Knopman D, Arai H, Doody RS, DeCarli C, Leight S, Lee VM, Trojanowski JQ, Arch Neurol 2003 60 12 1696 1702 10.1001/archneur.60.12.1696 14676043 (Pubitemid 37521622)
4. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S, Morris JC, N Engl J Med 2012 367 9 795 804 10.1056/NEJMoa1202753 22784036
5. Cerebrospinal fluid levels of beta-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O, Arch Gen Psychiatry 2012 69 1 98 106 10.1001/archgenpsychiatry.2011.155 22213792
6. Analytical aspects of molecular Alzheimer's disease biomarkers. Andreasson U, Vanmechelen E, Shaw LM, Zetterberg H, Vanderstichele H, Biomark Med 2012 6 4 377 389 10.2217/bmm.12.44 22917140
7. CSF biomarker variability in the Alzheimer's Association quality control program. Mattsson N, Andreasson U, Persson S, Carrillo MC, Collins S, Chalbot S, Cutler N, Dufour-Rainfray D, Fagan AM, Heegaard NH, Robin Hsiung GY, Hyman B, Iqbal K, Lachno DR, Lleó A, Lewczuk P, Molinuevo JL, Parchi P, Regeniter A, Rissman R, Rosenmann H, Sancesario G, Schröder J, Shaw LM, Teunissen CE, Trojanowski JQ, Vanderstichele H, Vandijck M, Verbeek MM, Zetterberg H, et al. Alzheimers Dement 2013 9 3 251 261 10.1016/j.jalz.2013.01.010 23622690
8. Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-beta1-42 and tau proteins as Alzheimer disease biomarkers. Kang JH, Korecka M, Toledo JB, Trojanowski JQ, Shaw LM, Clin Chem 2013 59 6 903 916 10.1373/clinchem.2013.202937 23519967
9. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Blennow K, Zetterberg H, Rinne JO, Salloway S, Wei J, Black R, Grundman M, Liu E, AAB-001 201/202 Investigators, Arch Neurol 2012 69 8 1002 1010 10.1001/archneurol.2012. 90 22473769
10. Proteomics of human cerebrospinal fluid: discovery and verification of biomarker candidates in neurodegenerative diseases using quantitative proteomics. Kroksveen AC, Opsahl JA, Aye TT, Ulvik RJ, Berven FS, J Proteomics 2011 74 4 371 388 10.1016/j.jprot.2010.11.010 21111852
11. Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease. Fagan AM, Perrin RJ, Biomark Med 2012 6 4 455 476 10.2217/bmm.12.42 22917147
12. Method of the Year 2012. Nat Methods 2013 10 1 1 23547284
13. Targeted proteomics. Marx V, Nat Methods 2013 10 1 19 22 23547293
14. Quantitative analysis of peptides and proteins in biomedicine by targeted mass spectrometry. Gillette MA, Carr SA, Nat Methods 2013 10 1 28 34 23269374
15. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. Abdi F, Quinn JF, Jankovic J, McIntosh M, Leverenz JB, Peskind E, Nixon R, Nutt J, Chung K, Zabetian C, Samii A, Lin M, Hattan S, Pan C, Wang Y, Jin J, Zhu D, Li GJ, Liu Y, Waichunas D, Montine TJ, Zhang J, J Alzheimers Dis 2006 9 3 293 348 16914840 (Pubitemid 44253348)
16. Neuronal pentraxin receptor in cerebrospinal fluid as a potential biomarker for neurodegenerative diseases. Yin GN, Lee HW, Cho JY, Suk K, Brain Res 2009 1265 158 170 19368810
17. Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Puchades M, Hansson SF, Nilsson CL, Andreasen N, Blennow K, Davidsson P, Brain Res Mol Brain Res 2003 118 1-2 140 146 14559363 (Pubitemid 37238996)
18. Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease. Finehout EJ, Franck Z, Choe LH, Relkin N, Lee KH, Ann Neurol 2007 61 2 120 129 10.1002/ana.21038 17167789 (Pubitemid 46363839)
19. Identification of a novel panel of cerebrospinal fluid biomarkers for Alzheimer's disease. Simonsen AH, McGuire J, Podust VN, Davies H, Minthon L, Skoog I, Andreasen N, Wallin A, Waldemar G, Blennow K, Neurobiol Aging 2008 29 7 961 968 10.1016/j.neurobiolaging.2007.01.011 17321007 (Pubitemid 351697984)
20. Comparative proteomic analysis of intra- and interindividual variation in human cerebrospinal fluid. Hu Y, Malone JP, Fagan AM, Townsend RR, Holtzman DM, Mol Cell Proteomics 2005 4 12 2000 2009 10.1074/mcp.M500207-MCP200 16199891 (Pubitemid 41830194)
21. Application of targeted quantitative proteomics analysis in human cerebrospinal fluid using a liquid chromatography matrix-assisted laser desorption/ionization time-of-flight tandem mass spectrometer (LC MALDI TOF/TOF) platform. Pan S, Rush J, Peskind ER, Galasko D, Chung K, Quinn J, Jankovic J, Leverenz JB, Zabetian C, Pan C, Wang Y, Oh JH, Gao J, Zhang J, Montine T, Zhang J, J Proteome Res 2008 7 2 720 730 10.1021/pr700630x 18186601 (Pubitemid 351294034)
22. Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease. Perrin RJ, Craig-Schapiro R, Malone JP, Shah AR, Gilmore P, Davis AE, Roe CM, Peskind ER, Li G, Galasko DR, Clark CM, Quinn JF, Kaye JA, Morris JC, Holtzman DM, Townsend RR, Fagan AM, PLoS One 2011 6 1 16032 10.1371/journal.pone.0016032 21264269
23. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, Mintun MA, Peskind ER, Li G, Galasko DR, Clark CM, Quinn JF, D'Angelo G, Malone JP, Townsend RR, Morris JC, Fagan AM, Holtzman DM, Biol Psychiatry 2010 68 10 903 912 10.1016/j.biopsych.2010.08.025 21035623
24. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA, Science 1993 261 5123 921 923 10.1126/science.8346443 8346443 (Pubitemid 23275809)
25. CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease. Tarawneh R, Lee JM, Ladenson JH, Morris JC, Holtzman DM, Neurology 2012 78 10 709 719 10.1212/WNL.0b013e318248e568 22357717
26. Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease. Tarawneh R, D'Angelo G, Macy E, Xiong C, Carter D, Cairns NJ, Fagan AM, Head D, Mintun MA, Ladenson JH, Lee JM, Morris JC, Holtzman DM, Ann Neurol 2011 70 2 274 285 10.1002/ana.22448 21823155
27. Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS. Gerber SA, Rush J, Stemman O, Kirschner MW, Gygi SP, Proc Natl Acad Sci U S A 2003 100 12 6940 6945 10.1073/pnas.0832254100 12771378 (Pubitemid 36706372)
28. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R, Nat Biotechnol 1999 17 10 994 999 10.1038/13690 10504701 (Pubitemid 29474856)
29. Application of an end-to-end biomarker discovery platform to identify target engagement markers in cerebrospinal fluid by high resolution differential mass spectrometry. Paweletz CP, Wiener MC, Bondarenko AY, Yates NA, Song Q, Liaw A, Lee AY, Hunt BT, Henle ES, Meng F, Sleph HF, Holahan M, Sankaranarayanan S, Simon AJ, Settlage RE, Sachs JR, Shearman M, Sachs AB, Cook JJ, Hendrickson RC, J Proteome Res 2010 9 3 1392 1401 10.1021/pr900925d 20095649
30. Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI. Ewers M, Buerger K, Teipel SJ, Scheltens P, Schröder J, Zinkowski RP, Bouwman FH, Schönknecht P, Schoonenboom NS, Andreasen N, Wallin A, DeBernardis JF, Kerkman DJ, Heindl B, Blennow K, Hampel H, Neurology 2007 69 24 2205 2212 10.1212/01.wnl.0000286944.22262.ff 18071141 (Pubitemid 350294675)
31. Plasma and CSF serpins in Alzheimer disease and dementia with Lewy bodies. Nielsen HM, Minthon L, Londos E, Blennow K, Miranda E, Perez J, Crowther DC, Lomas DA, Janciauskiene SM, Neurology 2007 69 16 1569 1579 10.1212/01.wnl.0000271077.82508.a0 17761554 (Pubitemid 350287140)
32. Reduced levels of amyloid-beta-binding proteins in cerebrospinal fluid from Alzheimer's disease patients. Hansson SF, Andréasson U, Wall M, Skoog I, Andreasen N, Wallin A, Zetterberg H, Blennow K, J Alzheimers Dis 2009 16 2 389 397 19221428
33. Structural and quantitative comparison of cerebrospinal fluid glycoproteins in Alzheimer's disease patients and healthy individuals. Sihlbom C, Davidsson P, Sjögren M, Wahlund LO, Nilsson CL, Neurochem Res 2008 33 7 1332 1340 10.1007/s11064-008-9588-x 18288611
34. Proteomic changes in cerebrospinal fluid of presymptomatic and affected persons carrying familial Alzheimer disease mutations. Ringman JM, Schulman H, Becker C, Jones T, Bai Y, Immermann F, Cole G, Sokolow S, Gylys K, Geschwind DH, Cummings JL, Wan HI, Arch Neurol 2012 69 1 96 104 10.1001/archneurol.2011.642 22232349
35. Biomarkers of Alzheimer's disease. Craig-Schapiro R, Fagan AM, Holtzman DM, Neurobiol Dis 2009 35 2 128 140 10.1016/j.nbd.2008.10.003 19010417
36. Amyloid precursor-like protein 1 accumulates in neuritic plaques in Alzheimer's disease. Bayer TA, Paliga K, Weggen S, Wiestler OD, Beyreuther K, Multhaup G, Acta Neuropathol 1997 94 6 519 524 10.1007/s004010050745 9444352 (Pubitemid 27511172)
37. Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients. Davidsson P, Westman-Brinkmalm A, Nilsson CL, Lindbjer M, Paulson L, Andreasen N, Sjögren M, Blennow K, Neuroreport 2002 13 5 611 615 10.1097/00001756- 200204160-00015 11973456 (Pubitemid 34293477)
38. A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. Carrette O, Demalte I, Scherl A, Yalkinoglu O, Corthals G, Burkhard P, Hochstrasser DF, Sanchez JC, Proteomics 2003 3 8 1486 1494 10.1002/pmic.200300470 12923774 (Pubitemid 37048074)
39. Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. Zhang J, Goodlett DR, Quinn JF, Peskind E, Kaye JA, Zhou Y, Pan C, Yi E, Eng J, Wang Q, Aebersold RH, Montine TJ, J Alzheimers Dis 2005 7 2 125 133 discussion 173-80 15851850 (Pubitemid 40592186)
40. Quantitative proteomic analysis of age-related changes in human cerebrospinal fluid. Zhang J, Goodlett DR, Peskind ER, Quinn JF, Zhou Y, Wang Q, Pan C, Yi E, Eng J, Aebersold RH, Montine TJ, Neurobiol Aging 2005 26 2 207 227 10.1016/j.neurobiolaging.2004.03.012 15582749 (Pubitemid 39610462)
41. Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment. Simonsen AH, McGuire J, Hansson O, Zetterberg H, Podust VN, Davies HA, Waldemar G, Minthon L, Blennow K, Arch Neurol 2007 64 3 366 370 10.1001/archneur.64.3.366 17353378 (Pubitemid 46425690)
42. Ceruloplasmin is increased in cerebrospinal fluid in Alzheimer's disease but not Parkinson's disease. Loeffler DA, DeMaggio AJ, Juneau PL, Brickman CM, Mashour GA, Finkelman JH, Pomara N, LeWitt PA, Alzheimer Dis Assoc Disord 1994 8 3 190 197 10.1097/00002093-199408030-00005 7986488 (Pubitemid 24282548)
43. Cerebrospinal fluid diagnostic markers correlate with lower plasma copper and ceruloplasmin in patients with Alzheimer's disease. Kessler H, Pajonk FG, Meisser P, Schneider-Axmann T, Hoffmann KH, Supprian T, Herrmann W, Obeid R, Multhaup G, Falkai P, Bayer TA, J Neural Transm 2006 113 11 1763 1769 10.1007/s00702-006-0485-7 16736242 (Pubitemid 44657672)
44. In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases. Bonneh-Barkay D, Wang G, Starkey A, Hamilton RL, Wiley CA, J Neuroinflammation 2010 7 34 10.1186/1742-2094-7-34 20540736
45. Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment. Hu WT, Chen-Plotkin A, Arnold SE, Grossman M, Clark CM, Shaw LM, Pickering E, Kuhn M, Chen Y, McCluskey L, Elman L, Karlawish J, Hurtig HI, Siderowf A, Lee VM, Soares H, Trojanowski JQ, Acta Neuropathol 2010 119 6 669 678 10.1007/s00401-010-0667-0 20232070
46. Chromogranin A in cerebrospinal fluid: a biochemical marker for synaptic degeneration in Alzheimer's disease? Blennow K, Davidsson P, Wallin A, Ekman R, Dementia 1995 6 6 306 311 8563783
47. Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis. Craig-Schapiro R, Kuhn M, Xiong C, Pickering EH, Liu J, Misko TP, Perrin RJ, Bales KR, Soares H, Fagan AM, Holtzman DM, PLoS One 2011 6 4 18850 10.1371/journal.pone.0018850 21526197
48. Complement 3 and factor h in human cerebrospinal fluid in Parkinson's disease, Alzheimer's disease, and multiple-system atrophy. Wang Y, Hancock AM, Bradner J, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Kim HM, Leverenz JB, Montine TJ, Ginghina C, Edwards KL, Snapinn KW, Goldstein DS, Shi M, Zhang J, Am J Pathol 2011 178 4 1509 1516 10.1016/j.ajpath.2011.01. 006 21435440
49. Complement protein isoforms in CSF as possible biomarkers for neurodegenerative disease. Finehout EJ, Franck Z, Lee KH, Dis Markers 2005 21 2 93 101 10.1155/2005/806573 15920296 (Pubitemid 40875153)
50. Identification and validation of novel CSF biomarkers for early stages of Alzheimer's disease. Hu Y, Hosseini A, Kauwe JS, Gross J, Cairns NJ, Goate AM, Fagan AM, Townsend RR, Holtzman DM, Proteomics Clin Appl 2007 1 11 1373 1384 10.1002/prca.200600999 21136637
51. Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease. Hu WT, Chen-Plotkin A, Arnold SE, Grossman M, Clark CM, Shaw LM, McCluskey L, Elman L, Karlawish J, Hurtig HI, Siderowf A, Lee VM, Soares H, Trojanowski JQ, Acta Neuropathol 2010 120 3 385 399 10.1007/s00401-010-0723-9 20652578
52. Total prion protein levels in the cerebrospinal fluid are reduced in patients with various neurological disorders. Meyne F, Gloeckner SF, Ciesielczyk B, Heinemann U, Krasnianski A, Meissner B, Zerr I, J Alzheimers Dis 2009 17 4 863 873 19542614
53. Both plasma retinol-binding protein and haptoglobin precursor allele 1 in CSF: candidate biomarkers for the progression of normal to mild cognitive impairment to Alzheimer's disease. Jung SM, Lee K, Lee JW, Namkoong H, Kim HK, Kim S, Na HR, Ha SA, Kim JR, Ko J, Kim JW, Neurosci Lett 2008 436 2 153 157 10.1016/j.neulet.2008.03.010 18378077
54. Combined analysis of the glia secretome and the CSF proteome: neuroinflammation and novel biomarkers. Suk K, Expert Rev Proteomics 2010 7 2 263 274 10.1586/epr.10.6 20377392
55. Cerebrospinal fluid transthyretin: aging and late onset Alzheimer's disease. Serot JM, Christmann D, Dubost T, Couturier M, J Neurol Neurosurg Psychiatry 1997 63 4 506 508 10.1136/jnnp.63.4.506 9343132 (Pubitemid 27423560)
56. Neuronal production of transthyretin in human and murine Alzheimer's disease: is it protective? Li X, Masliah E, Reixach N, Buxbaum JN, J Neurosci 2011 31 35 12483 12490 10.1523/JNEUROSCI.2417-11.2011 21880910
57. Stability of the transthyretin molecule as a key factor in the interaction with a-beta peptide-relevance in Alzheimer's disease. Ribeiro CA, Saraiva MJ, Cardoso I, PLoS One 2012 7 9 45368 10.1371/journal.pone.0045368 23028965
58. The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients. Lee JM, Blennow K, Andreasen N, Laterza O, Modur V, Olander J, Gao F, Ohlendorf M, Ladenson JH, Clin Chem 2008 54 10 1617 1623 10.1373/clinchem.2008.104497 18703769
59. Longitudinal stability of CSF biomarkers in Alzheimer's disease. Blennow K, Zetterberg H, Minthon L, Lannfelt L, Strid S, Annas P, Basun H, Andreasen N, Neurosci Lett 2007 419 1 18 22 10.1016/j.neulet.2007.03.064 17482358 (Pubitemid 46694097)
60. Longitudinal study of CSF biomarkers in patients with Alzheimer's disease. Buchhave P, Blennow K, Zetterberg H, Stomrud E, Londos E, Andreasen N, Minthon L, Hansson O, PLoS One 2009 4 7 6294 10.1371/journal.pone.0006294 19609443
61. Longitudinal changes of CSF biomarkers in memory clinic patients. Bouwman FH, van der Flier WM, Schoonenboom NS, van Elk EJ, Kok A, Rijmen F, Blankenstein MA, Scheltens P, Neurology 2007 69 10 1006 1011 10.1212/01.wnl.0000271375.37131.04 17785669 (Pubitemid 47366054)
62. Longitudinal stability evaluation of biomarkers and their correlation in cerebrospinal fluid and plasma from patients with Alzheimer's disease. Höglund K, Bogstedt A, Fabre S, Aziz A, Annas P, Basun H, Minthon L, Lannfelt L, Blennow K, Andreasen N, J Alzheimers Dis 2012 32 4 939 947 22936008
63. Longitudinal stability of cerebrospinal fluid biomarker levels: fulfilled requirement for pharmacodynamic markers in Alzheimer's disease. Le Bastard N, Aerts L, Sleegers K, Martin JJ, Van Broeckhoven C, De Deyn PP, Engelborghs S, J Alzheimers Dis 2013 33 3 807 822 23034521
64. Random-effects models for longitudinal data. Laird NM, Ware JH, Biometrics 1982 38 4 963 974 10.2307/2529876 7168798
65. Microglial markers are elevated in the prodromal phase of Alzheimer's disease and vascular dementia. Olsson B, Hertze J, Lautner R, Zetterberg H, Nägga K, Höglund K, Basun H, Annas P, Lannfelt L, Andreasen N, Minthon L, Blennow K, Hansson O, J Alzheimers Dis 2013 33 1 45 53 22890100
66. Albumin depletion of human plasma also removes low abundance proteins including the cytokines. Granger J, Siddiqui J, Copeland S, Remick D, Proteomics 2005 5 18 4713 4718 10.1002/pmic.200401331 16281180 (Pubitemid 43016893)
67. Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers. Ottervald J, Franzén B, Nilsson K, Andersson LI, Khademi M, Eriksson B, Kjellström S, Marko-Varga G, Végvári A, Harris RA, Laurell T, Miliotis T, Matusevicius D, Salter H, Ferm M, Olsson T, J Proteomics 2010 73 6 1117 1132 10.1016/j.jprot.2010.01.004 20093204
68. Longitudinal stability of CSF tau levels in Alzheimer patients. Sunderland T, Wolozin B, Galasko D, Levy J, Dukoff R, Bahro M, Lasser R, Motter R, Lehtimäki T, Seubert P, Biol Psychiatry 1999 46 6 750 755 10.1016/S0006-3223(99)00143-2 10494442 (Pubitemid 29460900)
69. Longitudinal changes of CSF biomarkers in Alzheimer's disease. Seppälä TT, Koivisto AM, Hartikainen P, Helisalmi S, Soininen H, Herukka SK, J Alzheimers Dis 2011 25 4 583 594 21460434
70. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. Fagan AM, Xiong C, Jasielec MS, Bateman RJ, Goate AM, Benzinger TL, Ghetti B, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Salloway S, Schofield PR, Sperling RA, Marcus D, Cairns NJ, Buckles VD, Ladenson JH, Morris JC, Holtzman DM, Dominantly Inherited Alzheimer Network, Sci Transl Med 2014 6 226 226ra30 10.1126/scitranslmed.3007901 24598588
71. Amyloid precursor protein trafficking, processing, and function. Thinakaran G, Koo EH, J Biol Chem 2008 283 44 29615 29619 10.1074/jbc.R800019200 18650430
72. The role of NrCAM in neural development and disorders-beyond a simple glue in the brain. Sakurai T, Mol Cell Neurosci 2012 49 3 351 363 10.1016/j.mcn.2011.12.002 22182708
73. Granins as disease-biomarkers: translational potential for psychiatric and neurological disorders. Bartolomucci A, Pasinetti GM, Salton SR, Neuroscience 2010 170 1 289 297 10.1016/j.neuroscience.2010.06.057 20600637
74. Editorial: chromogranin A at the crossroads of health and disease. Angelone T, Tota B, Curr Med Chem 2012 19 24 4039 4041 10.2174/ 092986712802430027 22834793
75. mGluR1/5-dependent long-term depression requires the regulated ectodomain cleavage of neuronal pentraxin NPR by TACE. Cho RW, Park JM, Wolff SB, Xu D, Hopf C, Kim JA, Reddy RC, Petralia RS, Perin MS, Linden DJ, Worley PF, Neuron 2008 57 6 858 871 10.1016/j.neuron.2008.01.010 18367087 (Pubitemid 351400630)
76. Neuronal pentraxins mediate silent synapse conversion in the developing visual system. Koch SM, Ullian EM, J Neurosci 2010 30 15 5404 5414 10.1523/JNEUROSCI.4893-09.2010 20392962
77. Synapse formation and function is modulated by the amyloid precursor protein. Priller C, Bauer T, Mitteregger G, Krebs B, Kretzschmar HA, Herms J, J Neurosci 2006 26 27 7212 7221 10.1523/JNEUROSCI.1450-06.2006 16822978
78. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. MacLean B, Tomazela DM, Shulman N, Chambers M, Finney GL, Frewen B, Kern R, Tabb DL, Liebler DC, MacCoss MJ, Bioinformatics 2010 26 7 966 968 10.1093/bioinformatics/btq054 20147306
79. nlme: Linear and nonlinear mixed effects models. Pinheiro J, Bates D, DebRoy S, Sarkar D, R Development Core Team, R Pckg V 2010 3 1 97